BEAM
$25.83
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
Recent News
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.
RBC Capital Maintains a Sector Perform Rating on Beam Therapeutics (BEAM), Here’s Why
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, RBC Capital adjusted the price target on Beam Therapeutics Inc. (NASDAQ:BEAM) to $26 from $22 and maintained a Sector Perform rating on the shares. The rating update came after the company reported its fiscal Q4 […]
Beam Therapeutics Clarifies Growth Path With PKU Program And New Financing
Beam Therapeutics (NasdaqGS:BEAM) launched BEAM-304, a new base-editing genetic medicine program for phenylketonuria, expanding its liver-targeted portfolio. The company entered a $500 million non-dilutive credit facility with Sixth Street to support the anticipated launch of its sickle cell therapy candidate, risto-cel. Beam reported continued progress across its clinical pipeline alongside these updates. Beam Therapeutics is drawing fresh attention as it adds a new program for...
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029.
Beam Therapeutics Inc. Q4 2025 Earnings Call Summary
Moby summary of Beam Therapeutics Inc.'s Q4 2025 earnings call